Emergent BioSolutions (NYSE:EBS – Get Rating) released its earnings results on Tuesday. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50), Briefing.com reports. The business had revenue of $165.10 million during the quarter, compared to analyst estimates of $142.85 million. Emergent BioSolutions had a negative net margin […]
Emergent BioSolutions (NYSE:EBS – Get Rating) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($3.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($1.50), Briefing.com reports. The business had revenue of $165.10 million during the quarter, compared to the consensus estimate of $142.85 million. Emergent BioSolutions had […]
Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 7,190,000 shares, a decline of 5.4% from the March 31st total of 7,600,000 shares. Based on an average trading volume of 1,720,000 shares, the short-interest ratio is […]
Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) have been assigned an average recommendation of “Hold” from the eight brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. […]
Emergent BioSolutions (NYSE:EBS – Get Rating) is set to issue its quarterly earnings data after the market closes on Tuesday, May 9th. Analysts expect the company to announce earnings of ($1.67) per share for the quarter. Emergent BioSolutions has set its FY 2023 guidance at EPS.Parties that wish to register for the company’s conference call […]